references/burn_and_portfolio.md
Burn, Runway, and R&D Portfolio Management
Reference for burn/runway tracking and risk-adjusted portfolio decisions. Pairs with burn_runway_tracker.py.
Burn and runway done honestly
Burn rate is cash spent per period; runway is cash-on-hand ÷ forward run-rate. The honest forward run-rate is the trailing (recent-weighted) burn, not the lifetime average — averages mask both an accelerating spend and a funded ramp. The tracker uses trailing burn and flags when trailing exceeds 115% of the lifetime average (an acceleration signal). Runway must be measured against value-inflection milestones: cash that runs out one month before analytical validation is materially worse than the same runway that clears it, because reaching the milestone changes the program's financing options and valuation.
Stage-gate portfolio management
Robert Cooper's Stage-Gate model structures R&D as a sequence of stages separated by go/kill gates. Each gate is a real-options decision: spend the next tranche, or kill and redeploy. The discipline is that money is committed one stage at a time, against pre-defined criteria — not as a lump sum at kickoff. This is why milestone-vs-cash alignment is the core runway question.
Risk-adjusted valuation
Raw NPV systematically overstates R&D value because it ignores attrition. Risk-adjusted NPV (rNPV) weights each phase's cash flows by the cumulative probability of success of reaching it — in drug development, the product of per-phase success rates (which compound to single-digit percentages from preclinical to approval). Real-options valuation goes further, pricing the optionality of being able to abandon. For portfolio ROI, always state whether the number is raw NPV or risk-adjusted; the difference is often an order of magnitude.
Efficiency benchmarks
Startup/SaaS efficiency frameworks (a16z's burn multiple, Bessemer's efficiency score) translate to R&D portfolios as "value created per dollar burned." They are blunt but useful for cross-program comparison when paired with milestone progress.
Sources
- Cooper, R.G., Winning at New Products: Creating Value Through Innovation, 5th ed. (2017) — Stage-Gate.
- Stewart, Allison & Johnson, Putting a price on biotechnology — Nature Biotechnology 2001 (rNPV in drug development).
- Trigeorgis, L., Real Options: Managerial Flexibility and Strategy in Resource Allocation (MIT Press).
- DiMasi, Grabowski & Hansen, Innovation in the pharmaceutical industry: New estimates of R&D costs — J Health Econ 2016 (attrition / phase success rates).
- a16z, The burn multiple and Bessemer State of the Cloud efficiency benchmarks.
- Chan & Thornhill, R&D portfolio management — R&D Management literature.